Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Transition state

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    37 result(s) found for: Transition state. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2007-001573-28 Sponsor Protocol Number: Uni-Koeln-320 Start Date*: 2007-11-26
    Sponsor Name:Universität zu Köln
    Full Title: Prevent: Secondary Prevention of Schizophrenia. A randomized controlled trial.
    Medical condition: Persons at risk of being prodromally symptomatic of psychosis (PAR)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-005004-13 Sponsor Protocol Number: NEURAPRO-E FINAL Protocol Start Date*: 2010-10-14
    Sponsor Name:Orygen Research Centre
    Full Title: Add-on Therapie mit Omega-3 Fettsäuren bei Jugendlichen mit hohem Risiko für Schizophrenie und andere psychotische Störungen: eine Multizentren- Replikationsstudie Omega-3 Fatty Acids for Symptomat...
    Medical condition: In view of recent data and after a careful review of potentially neuroprotective treatment options in early psychotic illness, we have decided to replicate the findings of a randomized controlled t...
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-004835-10 Sponsor Protocol Number: R092670SCH3015 Start Date*: 2016-03-23
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A 52-Week, Open-Label, Prospective, Multicenter, International Study of a Transition to the Paliperidone Palmitate 3-Month Formulation In Patients with Schizophrenia Previously Stabilized on the Pa...
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    18.1 10037175 - Psychiatric disorders 10039636 Schizophrenia simple PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) NL (Completed) DE (Completed) ES (Completed) DK (Completed) GR (Completed) HR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-005701-20 Sponsor Protocol Number: ANST2015_1 Start Date*: 2015-05-20
    Sponsor Name:Leiden University Medical Center
    Full Title: Shifting pain modulation towards anti-nociceptivity: Mechanism-specific pharmacological prevention of post sternotomy pain: the MASTER study
    Medical condition: chronic pain
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2022-000149-34 Sponsor Protocol Number: CR845-310302 Start Date*: 2023-01-17
    Sponsor Name:Cara Therapeutics, Inc.
    Full Title: A Multicenter, Randomized, Double-blind, Placebo-controlled 12-Week Study to Evaluate the Safety and Efficacy of Oral Difelikefalin in Advanced Chronic Kidney Disease Subjects with Moderate-to-Seve...
    Medical condition: Chronic Kidney Disease
    Disease: Version SOC Term Classification Code Term Level
    23.1 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended) PL (Prematurely Ended) BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-001104-41 Sponsor Protocol Number: ALXN1840-WD-204 Start Date*: 2020-07-22
    Sponsor Name:Alexion Pharmaceuticals, Inc.
    Full Title: A Phase 2, open-label study to assess copper and molybdenum balance in participants with Wilson disease treated with ALXN1840
    Medical condition: Wilson Disease (WD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10047988 Wilson's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2006-004265-34 Sponsor Protocol Number: R076477SCH3017 Start Date*: 2007-06-07
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: An Open-label Prospective Trial to Explore the Tolerability, Safety and Efficacy of Flexibly Dosed Paliperidone ER in Subjects With Schizophrenia
    Medical condition: schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    8.1 10039626 Schizophrenia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: LT (Completed) DE (Completed) FR (Completed) IT (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2013-001449-15 Sponsor Protocol Number: R668-AD-1225 Start Date*: 2013-12-05
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: AN OPEN-LABEL STUDY OF DUPILUMAB IN PATIENTS WITH ATOPIC DERMATITIS WHO PARTICIPATED IN PREVIOUS DUPILUMAB CLINICAL TRIALS
    Medical condition: Atopic dermatits
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000018018 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Completed) DE (Completed) PL (Completed) SE (Completed) LT (Completed) EE (Completed) DK (Completed) FI (Completed) ES (Completed) IT (Completed) NL (Completed) AT (Completed) BE (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2004-000016-10 Sponsor Protocol Number: 3098A1-201-EU Start Date*: 2004-10-12
    Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Research and Development
    Full Title: A 3-MONTH, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED, MULTICENTER, SAFETY, TOLERABILITY, AND EFFICACY STUDY OF 3 DOSES OF SRA-333 IN OUTPATIENTS WITH MILD TO MODERATE ALZHEIMER’S DISEASE WITH ...
    Medical condition: Alzheimer's Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-014410-10 Sponsor Protocol Number: CCD-0910-PR-0021 Start Date*: 2011-03-22
    Sponsor Name:Chiesi Farmaceutici SpA
    Full Title: A 12-week, multicentre, multinational, randomized, double-blind, double-dummy, 2-arm parallel group study comparing the efficacy and safety of Foster® 100/6 (beclomethasone dipropionate 100 µg plus...
    Medical condition: COPD (Chronic Obstructive Pulmonary Disease)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) SK (Completed) DE (Completed) DK (Completed) PL (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-004314-33 Sponsor Protocol Number: E2007-E044-301 Start Date*: 2006-02-02
    Sponsor Name:Eisai Limited
    Full Title: A Multi-centre, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of the Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients with Motor Fluc...
    Medical condition: Levodopa treated Parkinson's disease patients with motor fluctuations
    Disease: Version SOC Term Classification Code Term Level
    8.1 10061536
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) EE (Completed) GB (Completed) DE (Completed) AT (Completed) SE (Completed) HU (Completed) LT (Completed) CZ (Completed) ES (Completed) PT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-002004-39 Sponsor Protocol Number: BAT-2506-002-CR Start Date*: 2021-04-23
    Sponsor Name:Bio-Thera Solutions, Ltd.
    Full Title: A Multicenter, Double-blind, Randomized, Parallel-group Study to Compare the Efficacy and Safety of BAT2506 Versus Simponi® in Participants with Active Psoriatic Arthritis
    Medical condition: Psoriatic arthritis (PsA)
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2008-005305-19 Sponsor Protocol Number: D5130C00030 Start Date*: 2008-11-17
    Sponsor Name:AstraZeneca AB
    Full Title: A Randomised, Double-Blind, Outpatient, Crossover Study of the Anti-platelet Effects of AZD6140 Compared with Clopidogrel in Patients with Stable Coronary Artery Disease Previuosly Identified as Cl...
    Medical condition: Stable Coronary Artery Disease AZD6140 is under development for the prevention of thrombotic events in patients with non-ST and ST elevation coronary syndromes
    Disease: Version SOC Term Classification Code Term Level
    9.1 10011085 Ischaemic coronary artery disorders HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-000678-40 Sponsor Protocol Number: Vedolizumab-4013 Start Date*: 2016-08-19
    Sponsor Name:Takeda Development Centre Europe Limited
    Full Title: Entyvio (Vedolizumab IV) Extended Access Program in Ulcerative Colitis and Crohn’s Disease
    Medical condition: Ulcerative Colitis and Crohn’s Disease
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10045365 Ulcerative colitis LLT
    20.0 100000004856 10013099 Disease Crohns LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) CZ (Completed) HU (Completed) EE (Completed) BG (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-003109-73 Sponsor Protocol Number: TL-895-203 Start Date*: 2021-02-15
    Sponsor Name:Telios Pharma, Inc.
    Full Title: An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of TL-895 Combined with KRT-232 in Subjects with Relapsed/Refractory (R/R) FLT3+ Acute Myeloid Leukemia (AML)
    Medical condition: Relapsed/Refractory (R/R) FLT3+ Acute Myeloid Leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10081514 Acute myeloid leukemia refractory LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Prematurely Ended) AT (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-000951-29 Sponsor Protocol Number: 4658-102 Start Date*: 2017-06-22
    Sponsor Name:Sarepta Therapeutics, Inc.
    Full Title: An Open-Label Safety, Tolerability, and Pharmacokinetics Study of Eteplirsen in Young Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
    Medical condition: Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10013801 Duchenne muscular dystrophy PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) DE (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-002125-11 Sponsor Protocol Number: CT-P13-3.5 Start Date*: 2016-08-23
    Sponsor Name:Celltrion, Inc
    Full Title: A Randomized, Parallel-Group, Phase I/III Study to Evaluate Efficacy, Pharmacokinetics and Safety between Subcutaneous CT-P13 and Intravenous CT-P13 in Patients with Active Rheumatoid Arthritis
    Medical condition: Active Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) EE (Completed) HU (Completed) CZ (Completed) BG (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2020-004504-33 Sponsor Protocol Number: BAT-2206-002-CR Start Date*: 2021-07-20
    Sponsor Name:Bio-Thera Solutions, Ltd.
    Full Title: A Multicenter, Randomized, Double-Blind, Parallel-Arm, Phase 3 Study to Compare Efficacy and Safety of BAT2206 with Stelara® in Patients with Moderate to Severe Plaque Psoriasis
    Medical condition: Moderate to Severe Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10040785 Skin and subcutaneous tissue disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: View results
    EudraCT Number: 2019-001201-24 Sponsor Protocol Number: KRT-232-104 Start Date*: 2019-12-02
    Sponsor Name:Kartos Therapeutics, Inc.
    Full Title: An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined with Low-Dose Cytarabine (LDAC) or Decitabine in Patients with Acute Myeloid Leukemia (AML).
    Medical condition: Relapsed or refractory AML, AML secondary to myeloproliferative neoplasms (MPN), and JAK2 mutationpositive AML.
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) DE (Completed) GB (GB - no longer in EU/EEA) BE (Prematurely Ended) HU (Completed) PL (Completed) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-003076-22 Sponsor Protocol Number: PSY-201401_ESPRIT Start Date*: 2016-07-07
    Sponsor Name:Central Institute of Mental Health Mannheim (ZI)
    Full Title: Multimodal Prevention of First Psychotic Episode – a 2x2-Factorial Randomized Trial investigating the efficacy of Acetylcysteine (ACC) and Integrated Preventive Psychological Intervention (IPPI) in...
    Medical condition: Clinical High Risk state for developing a first psychotic episode
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10037175 Psychiatric disorders SOC
    20.0 10037175 - Psychiatric disorders 10061920 Psychotic disorder PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jun 09 13:09:20 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA